Evidence map›Paper›PMID 29144968›Full record

ArticleNeuron2017

A Synaptic Basis for GLP-1 Action in the Brain.

Sandrine Lefort, Matthias H Tschöp, Cristina García-Cáceres

Open access · greenAbstract readComment
PubMed Publisher
In one paragraph

Article in Neuron, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Obesity wars: may the smell be with you.American journal of physiology. Endocrinology and metabolism · 2023
    Review
  4. Nonclassical Islet Peptides: Pancreatic and Extrapancreatic Actions.Clinical medicine insights. Endocrinology and diabetes · 2019
    Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Sandrine LefortHelmholtz Diabetes Center and German Center for Diabetes Research (DZD), Helmholtz Zentrum München, München, Germany; Division of Metabolic Diseases, Department of Medicine, Technische Universität München, München, Germany.
Matthias H TschöpHelmholtz Diabetes Center and German Center for Diabetes Research (DZD), Helmholtz Zentrum München, München, Germany; Division of Metabolic Diseases, Department of Medicine, Technische Universität München, München, Germany.
Cristina García-CáceresHelmholtz Diabetes Center and German Center for Diabetes Research (DZD), Helmholtz Zentrum München, München, Germany; Division of Metabolic Diseases, Department of Medicine, Technische Universität München, München, Germany. Electronic address: garcia-caceres@helmholtz-muenchen.de.
Deutsches Diabetes-Zentrum e.V. · DEGerman Center for Diabetes Research · DETechnical University of Munich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unraveling the brain control of metabolism may generate opportunities to discover novel precision medicines for obesity and diabetes. In this issue of Neuron, Liu et al. (2017) identify a novel glucagon-like peptide (GLP)-1 receptor-dependent signaling process that exerts anorexigenic action via the regulation of AMPA receptor subunit composition in the hypothalamus.

Indexed as

Glucagon-Like Peptide 1Receptors, AMPABrainGlucagon-Like Peptide-1 ReceptorHypothalamusGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorReceptors, AMPA

Identifiers

PMID29144968
OpenAlexW2770015263

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.